Promoter holding
64.27%
SP
Standard Pharmaceuticals Ltd - Due diligence report
A 360° intelligence report on Standard Pharmaceuticals Ltd: trust score, financial health, credit view, compliance, directors, growth and di…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Standard Pharmaceuticals Ltd — 360° Intelligence Report
Generated from MCA filings & public records80/100
Trust Score
Low Risk
Standard Pharmaceuticals Ltd is assessed as Low Risk with a Trust Score of 80/100. Standard Pharmaceuticals Ltd is an active public limited indian non-government company incorporated in 1995, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 07 Jul 2026 from the latest processed filings. Standard Pharmaceuticals Ltd snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
80/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
50/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
55/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 3 open (21.36 cr) · 10 satisfied (45.30 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| The Federal Bank Ltd | 2 | 48.0 cr |
| Others | 2 | 48.0 cr |
| Religare Finvest Limited | 2 | 48.0 cr |
| Union Bank Of India | 4 | 48.0 cr |
| The Federal Bank Limited | 1 | 48.0 cr |
| The Federal Bank Ltd. | 1 | 48.0 cr |
Compliance Score: 50/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: NSDL.
- Litigation present in 4 court forum(s).
- 1 active GST registration(s).
Legal cases on record (4)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| TARUN MALL KUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| TARUN MALL KUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| BHABANI PRASAD DEY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| OMESH KUMAR SETHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Dwijasis Bhattacharya | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 5 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: TARUN MALL KUMAR (Whole-time director) · TARUN MALL KUMAR (CFO) · OMESH KUMAR SETHI (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 55 · Distress 90
Growth signals & trust indicators
Latest year revenue grew 1.42.
Asset base grew 2.1x - capacity expansion.
Operating for 30+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Compliance score is weak (50/100).
3 open charge(s) registered - assets are encumbered.
4 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence71/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment60/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 3 open charge(s) of 21.36 cr already registered.
- Compliance gaps should be priced into terms.
Investor view74/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events31 Oct 2025
Director appointed
Dwijasis Bhattacharya (Additional Director)
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
28 Aug 2024
Charge satisfied
Tata Capital Financial Services Limited
09 Sep 2020
Securities allotted
4600000 Equity Shares - 4.60 cr raised
14 Aug 2019
Securities allotted
500000 Equity Shares - 50.00 Lakh raised
27 Jun 2018
Charge created
Tata Capital Financial Services Limited - 84.50 Lakh
27 Apr 2018
Charge created
Others - 1.10 cr
25 Aug 2017
Charge created
Others - 12.85 cr
18 Aug 2017
Charge satisfied
Religare Finvest Limited
10 Aug 2017
Charge satisfied
The Federal Bank Ltd.
08 Dec 2016
Charge satisfied
The Federal Bank Ltd
30 Sep 2016
Director ceased
BHABANI PRASAD DEY
25 May 2016
Director appointed
BHABANI PRASAD DEY (Director)
Director ceased
PREM LATA MAGO
10
Key Observations
Auto-generated from the data aboveRevenue declined 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - leverage worth monitoring.
Net worth is positive.
5 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Mehin Total Chemicals Private Limited | U24211PB2009PTC032648 | Mansa, Punjab, India |
| Shubhan Inks And Chemicals Private Limited | U24100MH1996PTC098434 | Mumbai, Maharashtra, India |
| Robin Dyes And Intermediates Private Limited | U24231GJ1988PTC010981 | Surat, Gujarat, India |
| Suraiya Pvt Ltd | U51909GJ1948PTC000847 | Gujarat, Gujarat, India |
| International Homoeo Research Private Limited | U24234WB2003PTC095601 | Kolkata, West Bengal, India |
| Satya Cashew Chemicals Private Limited | U24117TN1988PTC015560 | 600061, Tamil Nadu, India |
| Alwar Paraffin And Allied Products Private Ltd | U74899DL1987PTC027616 | New Delhi, Delhi, India |
| Mil Laboratories Private Limited | U51507GJ2005PTC108602 | Savli, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Standard Pharmaceuticals Ltd before audits and certifications: compliance score 50/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Standard Pharmaceuticals Ltd: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 55/100, margin trends, ownership structure and peer set for Standard Pharmaceuticals Ltd - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 80/100, distress signals and MSME payment-delay disclosures - know whether Standard Pharmaceuticals Ltd pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Standard Pharmaceuticals Ltd - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Standard Pharmaceuticals Ltd an active company?
Standard Pharmaceuticals Ltd has MCA status “Active” with a compliance score of 50/100 (Moderate).
Is Standard Pharmaceuticals Ltd financially healthy?
Standard Pharmaceuticals Ltd has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.
Should I do business with Standard Pharmaceuticals Ltd?
Its overall Trust Score is 80/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Standard Pharmaceuticals Ltd?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 5 active director(s) are on record.
Does Standard Pharmaceuticals Ltd have loans or charges against its assets?
3 open charge(s) are registered against its assets, and 10 earlier charge(s) stand satisfied.
Is Standard Pharmaceuticals Ltd up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 50/100 (Moderate).
Is it risky to lend to Standard Pharmaceuticals Ltd?
Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
